The descriptive characteristics and distribution of patients according to chemoregimens.

Abbreviations: CEA: carcinoembryonic antigen; ECOG: Eastern Cooperative Oncology Group performance status; FL: 5-Fluorouracil (5-FU)/leucovorin; FOLFOX: mFOLFOX 6, 5-FU/leucovorin/oxaliplatin; LNR: the positive lymph node ratio of dissected lymph nodes; No.: number; OXA-based+ 5-FU-based: Oxaliplatin-based chemotherapy (less than 8 cycles of 5-FU/leucovorin/oxaliplatin or less than 6 cycles of oral capecitabine/intravenous oxaliplatin) followed by 5-FU-based chemotherapy (5-FU/leucovorin, oral tegafur-uracil/folinate calcium or oral capecitabine); P: probability value; TNM stage: Cancer staging system which was developed and is maintained by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) is based on the extent of the tumor (T), the extent of spread to the lymph nodes (N), and the presence of metastasis (M); UFUR: oral UFUR/LV, tegafur-uracil/oral folinate calcium (leucovorin); w/o: without; XELODA: oral capecitabine; XELOX: CapeOx, oral capecitabine/intravenous oxaliplatin; y/o: years old.